35
Participants
Start Date
May 1, 2019
Primary Completion Date
October 31, 2020
Study Completion Date
January 31, 2021
PEGPH20
PEGPH20 is a PEGylated, neutral-pH-active human hyaluronidase PH20 produced by recombinant DNA technology
Pembrolizumab
Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2
RECRUITING
Medical College of Wisconsin, Milwaukee
NOT_YET_RECRUITING
Cedars Sinai Medical Center, Los Angeles
NOT_YET_RECRUITING
Banner Health - MD Anderson Cancer Center, Gilbert
RECRUITING
University of Washington--Seattle Cancer Care Alliance, Seattle
ACTIVE_NOT_RECRUITING
Rutgers - Cancer Institute of New Jersey (CINJ), New Brunswick
Collaborators (1)
Merck Sharp & Dohme LLC
INDUSTRY
Halozyme Therapeutics
INDUSTRY
University of Washington
OTHER
Pancreatic Cancer Research Team
OTHER